Literature DB >> 29175113

Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal.

Alexander Batista-Duharte1, Damiana Téllez-Martínez2, Deivys Leandro Portuondo Fuentes2, Iracilda Zeppone Carlos2.   

Abstract

Adjuvants are substances used to enhance the efficacy of vaccines. They influence the magnitude and alter the quality of the adaptive immune response to vaccine antigens by amplifying or modulating different signals involved in the innate immune response. The majority of known adjuvants have been empirically identified. The limited immunogenicity of new vaccine antigens and the need for safer vaccines have increased the importance of identifying single, well-defined adjuvants with known cellular and molecular mechanisms for rational vaccine design. Depletion or functional inhibition of CD4+CD25+FoxP3+ regulatory T cells (Tregs) by molecular adjuvants has become an emergent approach in this field. Different successful results have been obtained for specific vaccines, but there are still unresolved issues such as the risk of autoimmune disease induction, the involvement of cells other than Tregs and optimization for different conditions. This work provides a comprehensive analysis of current approaches to inhibit Tregs with molecular adjuvants for vaccine improvement, highlights the progress being made, and describes ongoing challenges.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvants; Autoimmunity; CD25(+)FoxP3(+); Immune regulation; Regulatory T cells; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 29175113     DOI: 10.1016/j.phrs.2017.11.026

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

Review 1.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17

Review 2.  The dark side of Tregs during aging.

Authors:  Martina Palatella; Stephane M Guillaume; Michelle A Linterman; Jochen Huehn
Journal:  Front Immunol       Date:  2022-08-09       Impact factor: 8.786

Review 3.  Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches.

Authors:  Alexander Batista-Duharte; Fakhri Hassouneh; Pablo Alvarez-Heredia; Alejandra Pera; Rafael Solana
Journal:  Pharmaceutics       Date:  2022-08-17       Impact factor: 6.525

4.  Targeting Myeloid-Derived Suppressor Cells to Enhance a Trans-Sialidase-Based Vaccine Against Trypanosoma cruzi.

Authors:  Juan Cruz Gamba; Carolina Roldán; Estefanía Prochetto; Giuliana Lupi; Iván Bontempi; Carolina Verónica Poncini; Mónica Vermeulen; Ana Rosa Pérez; Iván Marcipar; Gabriel Cabrera
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

5.  Sporothrix schenckii Cell Wall Proteins-Stimulated BMDCs Are Able to Induce a Th1-Prone Cytokine Profile In Vitro.

Authors:  Camila Quinello; Lucas Souza Ferreira; Isabella Picolli; Maria Luiza Loesch; Deivys Leandro Portuondo; Alexander Batista-Duharte; Iracilda Zeppone Carlos
Journal:  J Fungi (Basel)       Date:  2018-09-02

6.  Foxp3 Silencing with Antisense Oligonucleotide Improves Immunogenicity of an Adjuvanted Recombinant Vaccine against Sporothrix schenckii.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Deivys Leandro Portuondo; Damiana Téllez-Martínez; Gladys Olivera; Manuel Fernández-Delgado; Beatriz Javega; Guadalupe Herrera; Alicia Martínez; Paulo Inacio Costa; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Int J Mol Sci       Date:  2021-03-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.